ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > DDC

DDC

概要

Name:Aromatic-L-amino-acid decarboxylase
Target Synonym:EC:4.1.1.28,EC 4.1.1,DDC,AADC,Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase),Aromatic-L-Amino-Acid Decarboxylase,Aromatic L-Amino Acid Decarboxylase,EC 4.1.1.28,DOPA decarboxylase
Number of Launched Drugs:8
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
DDC-H55H6 Human Human DDC / Dopa Decarboxilase Protein, His Tag (MALS verified)
DDC-H55H6-structure
DDC-H55H6-sds
ACRO Quality

生物活性データの一部

DDC-H55H6-ELISA
DDC MALS images

The purity of Human DDC, His Tag (Cat. No. DDC-H55H6) is more than 90% and the molecular weight of this protein is around 100-125 kDa verified by SEC-MALS.

Synonym Name

Aromatic-L-amino-acid decarboxylase,Dopa decarboxilase

Background

Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively.  DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Levodopa/Benserazide Hydrochloride Approved F. Hoffmann-La Roche Ltd Madopar Switzerland Parkinson Disease F. Hoffmann-La Roche Ltd 1973-06-27 Parkinson Disease Details
Eladocagene exuparvovec PTC-AADC Approved National Taiwan University, Ptc Therapeutics Inc Upstaza EU Amino Acid Metabolism, Inborn Errors Ptc Therapeutics International Ltd 2022-07-18 Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors Details
Levodopa/Carbidopa IPX-066; ABT-SLV-187; ND-0680; ND-0612L; AP-CD/LD; ND-0612; IPX-054; ABT-SLV187; IPX-203; CP-012; AP-09004; DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) Approved Merck Sharp & Dohme Corp Numient, Menesit, Duodopa, Vadova, Sinemet, Rytary, Isicom, Duopa, Flexilev, Nacom (imciromab), Nacom retard, Parcopa, DopaFuse, Patrome United States Parkinson Disease; Parkinson Disease, Secondary; Parkinson Disease, Postencephalitic Merck & Co Inc 1975-05-02 Albinism, Oculocutaneous; Diabetes Mellitus; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Albinism; Cocaine-Related Disorders; Amblyopia; Depressive Disorder, Treatment-Resistant; Cognitive Dysfunction; Motor Neuron Disease; Aphasia, Broca; Parkinson Disease; Stroke; Parkinson Disease, Postencephalitic; Depression; Parkinson Disease, Secondary; Gait Apraxia Details
Benserazide Hydrochloride Ro-4-4602 Approved Mainland China Parkinson Disease; Dyskinesias Shanghai Yishengyuan Pharmaceutical Co Ltd 1995-01-01 beta-Thalassemia; Dyskinesias; Parkinson Disease; Anemia, Sickle Cell Details
Foslevodopa/Foscarbidopa ABBV-951 Approved Abbvie Inc VYALEV, Vyalev, Duodopa, Produodopa Romania, Belgium, Cyprus Parkinson Disease Abbvie Deutschland Gmbh & Co Kg, Abbvie Sa, Abbvie Inc Parkinson Disease Details
Carbidopa/Entacapone/Levodopa ELC-200; ODM-101 Approved Orion Pharma Stalevo, LECIGon, Trigel, LECIGel, 达灵复 United States Parkinson Disease Orion Pharma A/S 2003-06-11 Parkinson Disease Details
Carbidopa MK-486 Approved Lodosyn United States Parkinson Disease Aton 1977-04-25 Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance Details
Carbidopa/Melevodopa V-1512; GT-1512; CHF-1512; CNP-1512 Approved Chiesi Farmaceutici SPA Sirio Italy Parkinson Disease null 2003-01-01 Parkinson Disease Details
Levodopa/Benserazide Hydrochloride Approved F. Hoffmann-La Roche Ltd Madopar Switzerland Parkinson Disease F. Hoffmann-La Roche Ltd 1973-06-27 Parkinson Disease Details
Eladocagene exuparvovec PTC-AADC Approved National Taiwan University, Ptc Therapeutics Inc Upstaza EU Amino Acid Metabolism, Inborn Errors Ptc Therapeutics International Ltd 2022-07-18 Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors Details
Levodopa/Carbidopa IPX-066; ABT-SLV-187; ND-0680; ND-0612L; AP-CD/LD; ND-0612; IPX-054; ABT-SLV187; IPX-203; CP-012; AP-09004; DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) Approved Merck Sharp & Dohme Corp Numient, Menesit, Duodopa, Vadova, Sinemet, Rytary, Isicom, Duopa, Flexilev, Nacom (imciromab), Nacom retard, Parcopa, DopaFuse, Patrome United States Parkinson Disease; Parkinson Disease, Secondary; Parkinson Disease, Postencephalitic Merck & Co Inc 1975-05-02 Albinism, Oculocutaneous; Diabetes Mellitus; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Albinism; Cocaine-Related Disorders; Amblyopia; Depressive Disorder, Treatment-Resistant; Cognitive Dysfunction; Motor Neuron Disease; Aphasia, Broca; Parkinson Disease; Stroke; Parkinson Disease, Postencephalitic; Depression; Parkinson Disease, Secondary; Gait Apraxia Details
Benserazide Hydrochloride Ro-4-4602 Approved Mainland China Parkinson Disease; Dyskinesias Shanghai Yishengyuan Pharmaceutical Co Ltd 1995-01-01 beta-Thalassemia; Dyskinesias; Parkinson Disease; Anemia, Sickle Cell Details
Foslevodopa/Foscarbidopa ABBV-951 Approved Abbvie Inc VYALEV, Vyalev, Duodopa, Produodopa Romania, Belgium, Cyprus Parkinson Disease Abbvie Deutschland Gmbh & Co Kg, Abbvie Sa, Abbvie Inc Parkinson Disease Details
Carbidopa/Entacapone/Levodopa ELC-200; ODM-101 Approved Orion Pharma Stalevo, LECIGon, Trigel, LECIGel, 达灵复 United States Parkinson Disease Orion Pharma A/S 2003-06-11 Parkinson Disease Details
Carbidopa MK-486 Approved Lodosyn United States Parkinson Disease Aton 1977-04-25 Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance Details
Carbidopa/Melevodopa V-1512; GT-1512; CHF-1512; CNP-1512 Approved Chiesi Farmaceutici SPA Sirio Italy Parkinson Disease null 2003-01-01 Parkinson Disease Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Buspirone/Carbidopa/Levodopa Phase 2 Clinical Universite Laval Spinal Cord Injuries; Multiple Sclerosis Details
Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) WD-1905 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) WD-1603 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa (Hengrui Medicine) HRG-2010 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Parkinson Disease Details
Ezaladcigene resoparvovec VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02 Phase 1 Clinical University Of California, Voyager Therapeutics Inc Aromatic amino acid decarboxylase deficiency; Parkinson Disease Details
Carbidopa/oxytriptan EVX-101 Phase 1 Clinical Evecxia Therapeutics Inc Depression Details
VGN-R09 VGN-R09b; VGN-R09 Phase 1 Clinical Shanghai Vitalgen BioPharma Co Ltd Aromatic amino acid decarboxylase deficiency Details
Levodopa/Carbidopa granule(WD Pharmaceutical) WD-2010 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa(WD Pharmaceutical) WD-1804 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Buspirone/Carbidopa/Levodopa Phase 2 Clinical Universite Laval Spinal Cord Injuries; Multiple Sclerosis Details
Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) WD-1905 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) WD-1603 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa (Hengrui Medicine) HRG-2010 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Parkinson Disease Details
Ezaladcigene resoparvovec VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02 Phase 1 Clinical University Of California, Voyager Therapeutics Inc Aromatic amino acid decarboxylase deficiency; Parkinson Disease Details
Carbidopa/oxytriptan EVX-101 Phase 1 Clinical Evecxia Therapeutics Inc Depression Details
VGN-R09 VGN-R09b; VGN-R09 Phase 1 Clinical Shanghai Vitalgen BioPharma Co Ltd Aromatic amino acid decarboxylase deficiency Details
Levodopa/Carbidopa granule(WD Pharmaceutical) WD-2010 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa(WD Pharmaceutical) WD-1804 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap